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n Defining Aspirin Resistance*
avid J. Schneider, MD, FACC
urlington, Vermont
spirin resistance is an increasingly common topic of
esearch and clinical discussion. From a clinical perspective,
atients who suffer a thrombotic event while taking aspirin
re considered by some to exhibit aspirin resistance. In this
ssue of the Journal, Tantry et al. (1) employ rigorous criteria
o identify a very low prevalence (0.5%, only 1 of 223
atients) of aspirin resistance. This low prevalence is in
ontrast to a much greater prevalence reported by others
ho have used a variety of criteria and methods to define
spirin resistance. The disparity may reflect multiple factors,
ncluding patient compliance, the mechanisms by which
spirin exerts its beneficial effects, and methods used to
mplicate aspirin resistance.
See page 1705
Tantry et al. (1) found that approximately 3% of patients
ere noncompliant. Thus, the majority of patients who
ere identified as being aspirin resistant in their study were
pseudoresistant” secondary to noncompliance. From a clin-
cal perspective, compliance with aspirin therapy must be
valuated and shown to be present among all patients in
hom aspirin resistance is ascribed. Both investigators and
linicians must evaluate and exclude noncompliance as a
ause of aspirin resistance.
Nearly 30 years ago, Roth and Majerus (2) demonstrated
hat the exposure of platelets to aspirin acetylates cylcooxy-
enase 1 and thereby inhibits production of thromboxane
2, a platelet agonist. Thromboxane A2 is released by
ctivated platelets and mediates the activation of additional
latelets. Thus, a primary pharmacological effect of aspirin
n platelets is to decrease recruitment and activation of
ther platelets. Although Roth and Majerus (2) demon-
trated acetylation of multiple other platelet proteins, func-
ional implications (particularly antiplatelet effects) of such
cetylation have not been defined. Thus, the recognized but
ot necessarily exclusive effect of aspirin on platelets is
nhibition of production of thromboxane A2 resulting from
cetylation of cylcooxygenase 1.
Additional antithrombotic properties of aspirin may be
ediated by its effect on coagulation factors such as fibrin-
gen (3) and factor XIII (4). Moreover, prevention of
ardiac events may be mediated, at least in part, by effects
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nstitute, University of Vermont, Burlington, Vermont.ndependent of effects of aspirin on platelets or the coagu-
ation cascade. For example, attenuation of inflammation by
ecreasing the release of inflammatory cytokines from leu-
ocytes may reduce the subsequent incidence of cardiac
vents (5). Variability in the effect of aspirin on any of these
henomena or on those that have not yet been defined may
ttenuate the beneficial effects of aspirin and contribute to
linical evidence of aspirin resistance. Accordingly, the
henomenon of aspirin resistance cannot be completely
elineated until all mechanisms by which aspirin exerts its
eneficial effects have been fully elucidated.
Tantry et al. (1) identified aspirin resistance by charac-
erizing the lack of attenuation of platelet activation in
esponse to an agonist, arichidonic acid that requires cyclo-
xygenase 1 for conversion to thromboxane A2. Thus,
atients defined as being aspirin resistant exhibited contin-
ed cyclooxygenase activity despite treatment with aspirin.
his narrow definition of aspirin resistance is defensible
ecause of its reliance on a defined pharmacologic effect of
spirin. A potential weakness is that it may not reflect
resistance” attributable to additional antithrombotic effects
f aspirin, such as the effect of aspirin on fibrinogen and
actor XIII. Nevertheless, specific criteria that reflect phar-
acologic resistance to aspirin are necessary to distinguish
rue aspirin resistance from increased platelet reactivity and
ther prothrombotic states despite treatment with aspirin.
ultiple genetic and environmental influences can alter
latelet reactivity and the propensity for thrombosis. In-
reased platelet reactivity has been associated with an
ncreased risk of cardiac events (6,7). Accordingly, patients
dentified as being aspirin resistant when less narrow criteria
re used to define aspirin resistance are likely to comprise a
eterogeneous group with increased platelet reactivity sec-
ndary to diverse environmental and genetic influences.
The greater risk of subsequent cardiac events in those
eemed to be aspirin resistant with the use of less narrow
riteria emphasizes the importance of uniform criteria for
efinition of aspirin resistance. Delineation of the molecu-
ar, genetic, and environmental mechanisms responsible for
ncreased platelet reactivity will likely identify novel targets
or therapy. Until this is possible, treatment of those with
ncreased platelet reactivity should include not only aspirin
ut also more powerful antiplatelet agents, such as clopi-
ogrel. Such treatment is likely to be associated with greater
enefit with respect to the prevention of cardiac events than
s treatment of an unselected group of patients with aspirin
lus clopidogrel.
The results of the important study by Tantry et al. (1)
nderscore the critical nature of the dependence of results
n the techniques used in specific studies. For example,
xposure of platelets to an agent that chelates calcium such
s sodium citrate alters both platelet reactivity (8) and the
ntiplatelet effects of glycoprotein IIb/IIIa antagonists (9).
n addition, inhibitory effects of antiplatelet agents are
nfluenced greatly by the particular agonist and the concen-
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November 1, 2005:1710–1 Editorial Commentrations chosen. These factors account for the unfortunate
eality that the development and successful clinical use of
lycoprotein IIb/IIIa antagonists was impeded initially by
imitations associated with the techniques used to assess
heir pharmacodynamic effect (10).
Tantry et al. (1) are to be commended for their perfor-
ance of a study that tested for aspirin resistance defined
pecifically, albeit narrowly, with respect to residual platelet
yclooxygenase 1 activity in the presence of aspirin. Moreover,
hey identified an important contributor to pseudoaspirin
esistance, patient noncompliance. Definition of specific
echanisms responsible for the greater incidence of persis-
ently increased platelet reactivity despite treatment with
spirin that has been called aspirin resistance in other
tudies should identify potentially novel and effective ther-
peutic targets. Lessons learned during the development of
lycoprotein IIb/IIIa antagonists and from the present study
nderscore the need for standardization of methods used to
haracterize platelet function.
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